<ul>
<li>小型股亮点：这三只股票在 2025 年上涨超过 300%</li>
</ul>
<p>GRAIL NASDAQ: GRAL 表示，尽管最近与其 NHS 研究相关的头条新闻，Galleri 多癌症早期检测测试的需求仍在持续增长，这是公司首席财务官 Aaron 在美国银行活动中所做的评论。</p>
<p>Aaron 说，NHS 更新引发了当前和潜在医生客户更多的问题，但他表示，那些超越头条新闻的医生关注临床效用指标，包括第四阶段癌症的减少、第一阶段和第二阶段检测的增加、急诊室就诊的减少，以及发现的癌症数量是标准护理的四倍。</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物技术的下一个重大突破</li>
</ul>
<p>“每个人都想看到 ASCO 数据，” Aaron 说，指的是预计在本月底进行的即将发布的演示。他表示，GRAIL 已扩大了其现场团队、销售团队和医疗销售团队，以便在数据发布后使用更新的材料并教育医生。</p>
<h2>预计未来 12 个月将进行 NHS 讨论</h2>
<p>在被问及与 NHS 的下一步时，Aaron 说 GRAIL 与试验有协议，并且公司已满足该过程中的一些临床效用终点。他表示，未来与 NHS 的讨论将涉及 “政治、预算和数据的平衡”，预计将在未来 12 个月内进行。</p>
<ul>
<li>2025 年表现优异的三只医疗技术股票</li>
</ul>
<p>他补充说，NHS 在评估如何与政府合作时 “有很多事情在进行”，但表示 GRAIL 继续与 NHS 官员进行对话，并期待讨论 “如何以及是否在其人群中实施这一点”。</p>
<p>Aaron 说，他不期望即将到来的 ASCO 演示会改变这些对话，指出 NHS 的关键人员已经对数据进行了 “了解”。</p>
<h2>FDA 审查在 1 月提交后继续进行</h2>
<p>在监管方面，Aaron 说 GRAIL 自 2018 年以来一直在 FDA 的突破性项目中，并在 1 月提交了审查包。他表示，FDA 已接受该包，审查正在进行中。</p>
<p>他说，NHS Galleri 数据被纳入该包中的是第一年的性能数据，而不是 NHS 研究的主要终点。Aaron 表示，GRAIL 在多个研究中重复了其性能结果，包括干预性和病例对照研究，并表示公司对正在审查的包充满信心。</p>
<p>在被问及 NHS 更新是否改变了与 FDA 的讨论基调时，Aaron 说：“没有。”</p>
<p>他说，FDA 已公开描述了如果没有召开咨询委员会会议，则审查时间为 180 天，如果召开咨询委员会，则为 320 天。GRAIL 目前尚不清楚是否会召开咨询委员会会议，但 Aaron 表示公司正在为此做准备。</p>
<h2>商业增长由自费和医生采用驱动</h2>
<p>Aaron 说，Galleri 仍然主要是自费测试，约 70% 的量来自自费客户。他表示，增长主要来自实体医生办公室，订购医生的数量和现有医生的重复订购都在增加。</p>
<p>他指出与 athenahealth、Quest Diagnostics 和 Epic Systems 的整合与合作伙伴关系是支持采用的工具。GRAIL 已宣布计划在年底前实施 Epic。</p>
<p>Aaron 还提到数字健康渠道作为一个新兴的增长机会，提到 Function Health、Everlywell 和 Hims &amp; Hers。他表示，这些平台接触到已经参与健康管理的消费者，并可能愿意自费进行检测。</p>
<p>在传统的医生渠道中，Aaron 表示 GRAIL 上个季度增加了约 1300 名医生，如果他记得没错的话。他表示，意识的提升是通过医学教育、社交媒体广告和允许医生分享测试经验的医生团体来推动的。</p>
<p>他说，GRAIL 的重测率现在超过 30%，他形容这是令人鼓舞的，因为该测试没有报销。他将这一数字与其他筛查测试进行了比较，后者在十年的报销后达到了约 30% 的重测率。</p>
<h2>报销、规模和成本结构仍然是关键关注领域</h2>
<p>Aaron 说，GRAIL 是为了广泛的人群访问而建立的，拥有能够在其 RTP 实验室每年进行超过 100 万次测试的基础设施，并且在同一建筑面积内有显著扩展的空间。</p>
<p>他概述了多条潜在的报销和广泛访问路径，包括与 NHS 和其他合作伙伴的国际机会，以及涉及 REACH 研究、CMS、MCED 法规和可能的 RAPID 规则的美国路径，这些规则可能允许 FDA 和 CMS 更快地合作进行突破性批准设备的报销。</p>
<p>根据 Aaron 的说法，REACH 研究将在三年内招募参与者，每位参与者进行三次抽血，最终结果预计在 2031 年初公布。他表示，目的是为 CMS 提供中期数据，以及 NHS 数据和真实世界证据。GRAIL 到目前为止已进行超过 50 万次商业测试。</p>
<p>在成本方面，Aaron 表示 GRAIL 当前的测试版本旨在支持在每次测试略高于 500 美元的报销水平下的 50% 到 60% 的利润率，他将其与 MCED 法规联系在一起。他表示，随着公司在其固定成本实验室基础设施中成长，利润率的改善应该会继续，并且进一步的成本降低可能来自规模和技术变革。</p>
<h2>竞争与长期战略</h2>
<p>Aaron 说，进入多癌症早期检测市场的其他公司帮助提高了医生的意识。他表示，GRAIL 仍然通过他所描述的干预性和前瞻性数据以及其 FDA 提交保持差异化。</p>
<p>他还表示，GRAIL 在微小残留病、治疗选择和复发监测方面具有能力，但公司仍然专注于多癌种早期检测。他提到 GRAIL 的资产负债表上大约有 8.3 亿美元，并可能在时机合适时考虑其他产品应用，但他补充说，现在在筛查之外投资将为时已晚。</p>
<p>当被问及关于 GRAIL 最常被误解的地方时，Aaron 表示公司的机会在于发现现有标准筛查未能检测到的癌症。他说，标准筛查在总体人群中仅能检测到约 14% 的癌症，并认为增加一种假阳性率低的检测可以使癌症检测更高效。</p>
<p>“这可能是我们找到、改变癌症死亡率曲线的最佳机会，” Aaron 说。</p>
<h2>关于 GRAIL NASDAQ: GRAL</h2>
<p>GRAIL, Inc NASDAQ: GRAL 是一家致力于通过多癌种血液检测进行早期癌症检测的生物技术公司。GRAIL 利用下一代测序、游离 DNA（cfDNA）分析和机器学习的进展，开发了 Galleri™测试，旨在在癌症的最早阶段识别超过 50 种癌症。该公司的平台分析循环肿瘤 DNA 中的甲基化模式，以确定肿瘤的存在及其来源组织，使医生能够进行及时的诊断跟进。</p>
<p>GRAIL 成立于 2016 年，作为 Illumina 的一个分拆公司，总部位于加利福尼亚州门洛帕克，并在英国设有额外的研究和运营中心。</p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GRAIL 吗？</h2>
<p>在考虑 GRAIL 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 GRAIL 并不在名单上。</p>
<p>虽然 GRAIL 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GRAL

基因改革 ETF - ARK

<p>GRAIL（纳斯达克股票代码：GRAL）报告称，尽管最近有关于 NHS 研究的头条新闻，其 Galleri 多癌症早期检测测试的需求仍在上升。首席财务官 Aaron 指出，关注临床益处的医生咨询量有所增加。GRAIL 正在与 NHS 进行持续讨论，并已向 FDA 提交了审查材料，目前正在审查中。该测试主要由个人自费，增长主要依赖于医生的采用和合作伙伴关系。GRAIL 的目标是实现广泛的可及性和报销，并具备支持每年超过 100 万次测试的基础设施</p>

<ul>
<li>Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股亮点：这三只股票在 2025 年上涨超过 300%</li>
</ul>
</div><p>GRAIL NASDAQ: GRAL said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event.</p>
<div class="lb-trans"><p>GRAIL NASDAQ: GRAL 表示，尽管最近与其 NHS 研究相关的头条新闻，Galleri 多癌症早期检测测试的需求仍在持续增长，这是公司首席财务官 Aaron 在美国银行活动中所做的评论。</p>
</div><p>Aaron said the NHS update prompted more questions from current and prospective physician customers, but he said physicians who looked beyond the headline focused on clinical utility measures including a reduction in Stage 4 cancers, an increase in Stage 1 and Stage 2 detections, decreased emergency room presentations and four times more cancers found than standard of care.</p>
<div class="lb-trans"><p>Aaron 说，NHS 更新引发了当前和潜在医生客户更多的问题，但他表示，那些超越头条新闻的医生关注临床效用指标，包括第四阶段癌症的减少、第一阶段和第二阶段检测的增加、急诊室就诊的减少，以及发现的癌症数量是标准护理的四倍。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物技术的下一个重大突破</li>
</ul>
</div><p>“Everybody wants to see the ASCO data,” Aaron said, referring to the upcoming presentation expected at the end of the month. He said GRAIL has expanded its field team, sales force and medical sales team so they can use updated materials and educate physicians once the data are presented.</p>
<div class="lb-trans"><p>“每个人都想看到 ASCO 数据，” Aaron 说，指的是预计在本月底进行的即将发布的演示。他表示，GRAIL 已扩大了其现场团队、销售团队和医疗销售团队，以便在数据发布后使用更新的材料并教育医生。</p>
</div><h2>NHS Discussions Expected Over Next 12 Months</h2>
<div class="lb-trans"><h2>预计未来 12 个月将进行 NHS 讨论</h2>
</div><p>Asked about next steps with the NHS, Aaron said GRAIL has an agreement tied to the trial and that the company has met some of the clinical utility endpoints included in that process. He said future discussions with the NHS will involve “a balance of politics, budget, and data,” and are expected to take place over the next 12 months.</p>
<div class="lb-trans"><p>在被问及与 NHS 的下一步时，Aaron 说 GRAIL 与试验有协议，并且公司已满足该过程中的一些临床效用终点。他表示，未来与 NHS 的讨论将涉及 “政治、预算和数据的平衡”，预计将在未来 12 个月内进行。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现优异的三只医疗技术股票</li>
</ul>
</div><p>He added that the NHS has “a lot going on” as it evaluates how it operates with the government, but said GRAIL continues to talk with NHS officials and looks forward to discussing “how and if this gets implemented in their population.”</p>
<div class="lb-trans"><p>他补充说，NHS 在评估如何与政府合作时 “有很多事情在进行”，但表示 GRAIL 继续与 NHS 官员进行对话，并期待讨论 “如何以及是否在其人群中实施这一点”。</p>
</div><p>Aaron said he does not expect the upcoming ASCO presentation to change those conversations, noting that key people at the NHS have already been “read in” on the data.</p>
<div class="lb-trans"><p>Aaron 说，他不期望即将到来的 ASCO 演示会改变这些对话，指出 NHS 的关键人员已经对数据进行了 “了解”。</p>
</div><h2>FDA Review Continues After January Submission</h2>
<div class="lb-trans"><h2>FDA 审查在 1 月提交后继续进行</h2>
</div><p>On the regulatory front, Aaron said GRAIL has been in the FDA’s breakthrough program since 2018 and submitted its review package in January. He said the FDA has accepted the package and that the review is ongoing.</p>
<div class="lb-trans"><p>在监管方面，Aaron 说 GRAIL 自 2018 年以来一直在 FDA 的突破性项目中，并在 1 月提交了审查包。他表示，FDA 已接受该包，审查正在进行中。</p>
</div><p>He said the NHS Galleri data being included in the package were first-year performance data, not the primary endpoint of the NHS study. Aaron said GRAIL has repeated its performance results across multiple studies, including interventional and case-control studies, and said the company is confident in the package under review.</p>
<div class="lb-trans"><p>他说，NHS Galleri 数据被纳入该包中的是第一年的性能数据，而不是 NHS 研究的主要终点。Aaron 表示，GRAIL 在多个研究中重复了其性能结果，包括干预性和病例对照研究，并表示公司对正在审查的包充满信心。</p>
</div><p>Asked whether the NHS update had changed the tone of FDA discussions, Aaron said, “No.”</p>
<div class="lb-trans"><p>在被问及 NHS 更新是否改变了与 FDA 的讨论基调时，Aaron 说：“没有。”</p>
</div><p>He said the FDA has publicly described a 180-day review timeline if no advisory committee meeting is held, and a 320-day timeline if an advisory committee is convened. GRAIL does not yet know whether there will be an advisory committee meeting, but Aaron said the company is preparing for one.</p>
<div class="lb-trans"><p>他说，FDA 已公开描述了如果没有召开咨询委员会会议，则审查时间为 180 天，如果召开咨询委员会，则为 320 天。GRAIL 目前尚不清楚是否会召开咨询委员会会议，但 Aaron 表示公司正在为此做准备。</p>
</div><h2>Commercial Growth Driven by Self-Pay and Physician Adoption</h2>
<div class="lb-trans"><h2>商业增长由自费和医生采用驱动</h2>
</div><p>Aaron said Galleri remains primarily a self-pay test, with about 70% of volume coming from self-pay customers. He said growth is being driven by brick-and-mortar physician offices, where both the number of ordering physicians and repeat ordering by existing physicians have expanded.</p>
<div class="lb-trans"><p>Aaron 说，Galleri 仍然主要是自费测试，约 70% 的量来自自费客户。他表示，增长主要来自实体医生办公室，订购医生的数量和现有医生的重复订购都在增加。</p>
</div><p>He pointed to integrations and partnerships with athenahealth, Quest Diagnostics and Epic Systems as tools that can support adoption. GRAIL has announced plans to implement Epic by the end of the year.</p>
<div class="lb-trans"><p>他指出与 athenahealth、Quest Diagnostics 和 Epic Systems 的整合与合作伙伴关系是支持采用的工具。GRAIL 已宣布计划在年底前实施 Epic。</p>
</div><p>Aaron also cited digital health channels as an emerging growth opportunity, naming Function Health, Everlywell and Hims &amp; Hers. He said these platforms reach consumers who are already engaged in managing their health and may be willing to pay out of pocket for testing.</p>
<div class="lb-trans"><p>Aaron 还提到数字健康渠道作为一个新兴的增长机会，提到 Function Health、Everlywell 和 Hims &amp; Hers。他表示，这些平台接触到已经参与健康管理的消费者，并可能愿意自费进行检测。</p>
</div><p>In traditional physician channels, Aaron said GRAIL added about 1,300 physicians last quarter, if he recalled correctly. He said awareness is being driven by medical education, social media advertising and physician groups that allow doctors to share experiences with the test.</p>
<div class="lb-trans"><p>在传统的医生渠道中，Aaron 表示 GRAIL 上个季度增加了约 1300 名医生，如果他记得没错的话。他表示，意识的提升是通过医学教育、社交媒体广告和允许医生分享测试经验的医生团体来推动的。</p>
</div><p>He said GRAIL’s retest rate is now above 30%, which he described as encouraging given that the test is not reimbursed. He compared that figure with other screening tests that have reached about a 30% retest rate after a decade of reimbursement.</p>
<div class="lb-trans"><p>他说，GRAIL 的重测率现在超过 30%，他形容这是令人鼓舞的，因为该测试没有报销。他将这一数字与其他筛查测试进行了比较，后者在十年的报销后达到了约 30% 的重测率。</p>
</div><h2>Reimbursement, Scale and Cost Structure Remain Key Focus Areas</h2>
<div class="lb-trans"><h2>报销、规模和成本结构仍然是关键关注领域</h2>
</div><p>Aaron said GRAIL was built for broad population access and has infrastructure capable of running more than 1 million tests annually at its RTP lab, with room to expand significantly within the same building footprint.</p>
<div class="lb-trans"><p>Aaron 说，GRAIL 是为了广泛的人群访问而建立的，拥有能够在其 RTP 实验室每年进行超过 100 万次测试的基础设施，并且在同一建筑面积内有显著扩展的空间。</p>
</div><p>He outlined multiple potential paths to reimbursement and broad access, including international opportunities with the NHS and other partners, as well as U.S. pathways involving the REACH study, CMS, MCED legislation and possible RAPID rules that could allow FDA and CMS to work together more quickly on reimbursement for breakthrough-approved devices.</p>
<div class="lb-trans"><p>他概述了多条潜在的报销和广泛访问路径，包括与 NHS 和其他合作伙伴的国际机会，以及涉及 REACH 研究、CMS、MCED 法规和可能的 RAPID 规则的美国路径，这些规则可能允许 FDA 和 CMS 更快地合作进行突破性批准设备的报销。</p>
</div><p>According to Aaron, the REACH study is enrolling participants over three years, with three blood draws per participant and a final readout expected around early 2031. He said the intent is to provide interim data for CMS, alongside NHS data and real-world evidence. GRAIL has performed more than half a million commercial tests to date, he said.</p>
<div class="lb-trans"><p>根据 Aaron 的说法，REACH 研究将在三年内招募参与者，每位参与者进行三次抽血，最终结果预计在 2031 年初公布。他表示，目的是为 CMS 提供中期数据，以及 NHS 数据和真实世界证据。GRAIL 到目前为止已进行超过 50 万次商业测试。</p>
</div><p>On costs, Aaron said GRAIL’s current test version is designed to support margins in the 50% to 60% range at reimbursement levels of slightly above $500 per test, which he linked to MCED legislation. He said margin improvement should continue as the company grows into its fixed-cost laboratory infrastructure, and that further cost reductions could come from scale and technology changes.</p>
<div class="lb-trans"><p>在成本方面，Aaron 表示 GRAIL 当前的测试版本旨在支持在每次测试略高于 500 美元的报销水平下的 50% 到 60% 的利润率，他将其与 MCED 法规联系在一起。他表示，随着公司在其固定成本实验室基础设施中成长，利润率的改善应该会继续，并且进一步的成本降低可能来自规模和技术变革。</p>
</div><h2>Competition and Long-Term Strategy</h2>
<div class="lb-trans"><h2>竞争与长期战略</h2>
</div><p>Aaron said additional companies entering the multi-cancer early detection market have helped raise awareness among physicians. He said GRAIL remains differentiated by what he described as interventional and prospective data, as well as its FDA submission.</p>
<div class="lb-trans"><p>Aaron 说，进入多癌症早期检测市场的其他公司帮助提高了医生的意识。他表示，GRAIL 仍然通过他所描述的干预性和前瞻性数据以及其 FDA 提交保持差异化。</p>
</div><p>He also said GRAIL has capabilities in minimal residual disease, therapy selection and recurrence monitoring, but that the company remains focused on multi-cancer early detection. He said GRAIL has about $830 million on its balance sheet and may consider other product applications when the timing is right, but added that investing outside screening now would be premature.</p>
<div class="lb-trans"><p>他还表示，GRAIL 在微小残留病、治疗选择和复发监测方面具有能力，但公司仍然专注于多癌种早期检测。他提到 GRAIL 的资产负债表上大约有 8.3 亿美元，并可能在时机合适时考虑其他产品应用，但他补充说，现在在筛查之外投资将为时已晚。</p>
</div><p>Asked what is most misunderstood about GRAIL, Aaron said the company’s opportunity is to find cancers beyond those detected by existing standard-of-care screening. He said standard screening detects about 14% of cancers in the population, and argued that adding one test with a low false-positive rate could make cancer detection more efficient.</p>
<div class="lb-trans"><p>当被问及关于 GRAIL 最常被误解的地方时，Aaron 表示公司的机会在于发现现有标准筛查未能检测到的癌症。他说，标准筛查在总体人群中仅能检测到约 14% 的癌症，并认为增加一种假阳性率低的检测可以使癌症检测更高效。</p>
</div><p>“It’s probably the best shot we have at finding, at bending the cancer mortality curve,” Aaron said.</p>
<div class="lb-trans"><p>“这可能是我们找到、改变癌症死亡率曲线的最佳机会，” Aaron 说。</p>
</div><h2>About GRAIL NASDAQ: GRAL</h2>
<div class="lb-trans"><h2>关于 GRAIL NASDAQ: GRAL</h2>
</div><p>GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.</p>
<div class="lb-trans"><p>GRAIL, Inc NASDAQ: GRAL 是一家致力于通过多癌种血液检测进行早期癌症检测的生物技术公司。GRAIL 利用下一代测序、游离 DNA（cfDNA）分析和机器学习的进展，开发了 Galleri™测试，旨在在癌症的最早阶段识别超过 50 种癌症。该公司的平台分析循环肿瘤 DNA 中的甲基化模式，以确定肿瘤的存在及其来源组织，使医生能够进行及时的诊断跟进。</p>
</div><p>Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.</p>
<div class="lb-trans"><p>GRAIL 成立于 2016 年，作为 Illumina 的一个分拆公司，总部位于加利福尼亚州门洛帕克，并在英国设有额外的研究和运营中心。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GRAIL Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GRAIL 吗？</h2>
</div><p>Before you consider GRAIL, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GRAIL 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 GRAIL 并不在名单上。</p>
</div><p>While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GRAIL 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

Market Beat

GRAIL

美国银行

奎斯特诊疗

Hims & Hers Health

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

GRAIL 称，Galleri 的需求正在上升，同时与英国国家医疗服务体系的谈判和美国食品药品监督管理局的审查也在推进